Pleiotropic actions of fenofibrate on the heart

被引:34
作者
Balakumar, Pitchai [1 ]
Rohilla, Ankur [2 ]
Mahadevan, Nanjaian [1 ]
机构
[1] Rajendra Inst Technol & Sci, Inst Pharm, Dept Pharmacol, Sirsa 125055, India
[2] Shri Gopi Chand Grp Inst, Dept Pharmaceut Sci, Baghpat 250609, India
关键词
Fenofibrate; PPAR-alpha; Cardiac pleiotropic action; Cardioprotection; ACTIVATED-RECEPTOR-ALPHA; VASCULAR ENDOTHELIAL DYSFUNCTION; CHRONIC PRESSURE-OVERLOAD; PPAR-ALPHA; CARDIAC-HYPERTROPHY; INDUCED HYPERTENSION; GAMMA ACTIVATORS; RATS; FIBROSIS; APOPTOSIS;
D O I
10.1016/j.phrs.2010.11.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced levels of high-density lipoproteins (HDL) in the circulation. Fenofibrate has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL, and thus it is used to manage dyslipidemia. The lipid lowering effects of fenofibrate are classically mediated via an activation of peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Recent studies demonstrated numerous pleiotropic effects of fenofibrate on the heart that afford direct myocardial protection besides its lipid lowering effects. Fenofibrate has an additional potential to prevent the induction and progression of hypertensive heart damage, cardiac hypertrophy, heart failure, myocarditis, lipotoxic cardiomyopathy and vascular endothelial dysfunction-associated cardiovascular abnormalities. In this review, we critically discussed recently identified pleiotropic actions of fenofibrate on the heart. Moreover, the novel cardioprotective effects of fenofibrate against various cardiac disorders have been delineated. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 44 条
[1]   Combined therapy with PPARα agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency [J].
Asai, Toru ;
Okumura, Kenji ;
Takahashi, Ryotaro ;
Matsui, Hideo ;
Numaguchi, Yasushi ;
Murakami, Hisashi ;
Murakami, Ryulchiro ;
Murohara, Toyoaki .
CARDIOVASCULAR RESEARCH, 2006, 70 (03) :566-577
[2]   Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions [J].
Balakumar, Pitchai ;
Kaur, Tajpreet ;
Singh, Manjeet .
TOXICOLOGY, 2008, 245 (1-2) :49-64
[3]   Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared? [J].
Balakumar, Pitchai ;
Jagadeesh, Gowraganahalli .
PHARMACOLOGICAL RESEARCH, 2010, 62 (05) :365-383
[4]   Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? [J].
Balakumar, Pitchai ;
Kaur, Jagdeep .
PHARMACOLOGICAL RESEARCH, 2009, 60 (05) :361-368
[5]   Emerging role of PPAR ligands in the management of diabetic nephropathy [J].
Balakumar, Pitchai ;
Arora, Mandeep Kumar ;
Singh, Manjeet .
PHARMACOLOGICAL RESEARCH, 2009, 60 (03) :170-173
[6]   Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat [J].
Balakumar, Pitchai ;
Chakkarwar, Vishal Arvind ;
Singh, Manjeet .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2009, 320 (1-2) :149-162
[7]   Targeting Apoptosis in the Heart of Streptozotocin-Induced Diabetic Rats [J].
Baraka, Azza ;
AbdelGawad, Hala .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 15 (02) :175-181
[8]   The PPARα activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy [J].
Brigadeau, Francois ;
Gele, Patrick ;
Wibaux, Maud ;
Marquie, Christelle ;
Martin-Nizard, Francoise ;
Torpier, Gerard ;
Fruchart, Jean-Charles ;
Staels, Bart ;
Duriez, Patrick ;
Lacroix, Dominique .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (06) :408-415
[9]  
Chen Hong-juan, 2007, Zhejiang Da Xue Xue Bao Yi Xue Ban, V36, P470
[10]   Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats [J].
De Ciuceis, C. ;
Amiri, F. ;
Iglarz, M. ;
Cohn, J. S. ;
Touyz, R. M. ;
Schiffrin, E. L. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (01) :45-53